Accustem Sciences Reports Zero Revenue, Q1 Net Loss Widens to $(485,883)
ACUT sits 21% above its 52-week low of $0.216 on light trading volume (0.1× avg).
Summary
Accustem Sciences Inc. reported Q1 2026 financial results, showing zero revenue and a net loss of $(485,883), which widened by approximately 10% year-over-year compared to Q1 2025. This latest quarterly update reinforces the severe financial challenges highlighted in the company's recent 10-K filing from April 14, 2026, which included a going concern warning and critically low cash. The continued lack of revenue and ongoing cash burn underscore the company's precarious financial position and urgent need for capital. Traders will closely monitor any future financing activities and the company's progress towards its stated goal of commercializing its MSC assay in early 2027.
At the time of this announcement, ACUT was trading at $0.26 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.2M. The 52-week trading range was $0.22 to $2.33. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.